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Abstract 
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with great variability in 
disease severity and rate of progression. The need for a reliable, sensitive, and 
objective biomarker to track disease progression and response to therapy remains a 
great challenge in IPF clinical trials. Over the past decade, quantitative computed 
tomography (QCT) has emerged as an area of intensive research to address this need. 
We have gathered a group of pulmonologists, radiologists and scientists with expertise 
in this area to define the current status and future promise of this imaging technique in 
the evaluation and management of IPF. In this Pulmonary Perspective, we review the 
development and validation of six computer-based QCT methods and offer insight into 
the optimal use of an imaging-based biomarker as a tool for prognostication, prediction 
of response to therapy, and potential surrogate endpoint in future therapeutic trials.  
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Introduction 
Idiopathic pulmonary fibrosis (IPF) is the classic fibrosing interstitial lung disease (ILD). 
While inexorably progressive, its natural history is inconsistent and unpredictable (1, 
2).This variability in the rate and severity of disease progression makes prognostication 
for individual patients challenging and creates significant barriers to efficient drug 
development. Validation of a sensitive, reproducible and objective biomarker that 
accurately tracks disease progression and response to therapy would be of enormous 
benefit. High-resolution computed tomography (HRCT) of the chest is routinely 
performed in patients with suspected fibrotic lung disease and is widely available, 
making it a promising target for biomarker research (3). Although there is ample 
evidence that HRCT provides prognostic information in IPF, qualitative visual 
assessment is limited by inter-observer variability (4). In contrast, computer-based 
methods for quantifying disease on HRCT could provide rapid, objective measurement 
of disease extent and change over time. We convened a group of chest radiologists and 
pulmonary clinicians with IPF expertise, scientists with expertise in computational image 
analysis, and key individuals from the pharmaceutical industry to address the optimal 
approach to developing image-based biomarkers for diagnosis, prognosis and 
monitoring of response to therapy in IPF.  
 
Background 
Imaging Endpoints and Biomarkers in IPF 
The Biomarkers Definitions Working Group defines a clinical endpoint as a variable that 
reflects how a patient feels, functions, or survives (5, 6). The past three decades of IPF 
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clinical trial design have struggled to find a clinical primary endpoint that can be 
routinely used. Although all-cause mortality is a well-defined, reliable, and easy to 
measure primary endpoint, its use in IPF is limited due to low event rates (7). Therefore, 
in the absence of an ideal endpoint such as mortality, the substitution of a validated 
biomarker for a clinical endpoint (i.e. a surrogate endpoint) that can reliably predict the 
effect of the therapy can significantly improve the efficiency of IPF clinical trials (8-10). 
While quality of life and functional status instruments are predictive of mortality 
and show promise as potential biomarkers, these measures may not reflect therapeutic 
impact commensurate with survival (6). Forced vital capacity (FVC) is widely considered 
an accepted surrogate endpoint in IPF clinical trials and is routinely used as a primary 
endpoint. However, it is prone to missing data, may miss important treatment effects, 
and as currently approved therapies affect its rate of decline, its use in future trials may 
be less compelling (11-13). Quantitative computed tomography (QCT) can be 
reproducibly performed across the spectrum of disease severity. Currently available 
data support the ability of QCT to measure baseline disease severity and progression 
making it potentially an attractive surrogate endpoint (14, 15).  
 
Challenges in Qualifying a Biomarker  
We seek to establish the clinical value of existing imaging-based biomarkers as 
prognostic factors (the effects of patient-specific or IPF characteristics on patient 
outcome), predictive factors (the effects of treatment on IPF), and surrogate endpoints 
in the setting of IPF (16). As a prognostic factor it is objectively measurable and might 
provide information on the likely outcome of IPF in an untreated individual. As a 
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predictive factor, it might provide information on the likely benefit from treatment (either 
in terms of physiologic outcome or survival). Such predictive factors can be used to 
identify subpopulations of patients or specific phenotypes that are most likely to benefit 
from a given therapy.  
 
Imaging Biomarker Development and Validation 
In the development and qualification of an imaging biomarker, there are three important 
phases: (1) development (including training of classifiers), (2) analytic validation 
(determination of cut points, assessment of reproducibility, and evaluation against 
radiologist measurements), and (3) clinical validation in which the system and its cut 
points are fixed and it is evaluated against outcomes in new clinical trial data. In the 
development phase, a supervised classification model is usually constructed using 
regions of interest with parenchymal abnormalities identified and classified visually by 
an expert thoracic radiologist. Test validation studies are then performed to estimate the 
variation of measurement and clarify the cut points for the intended use of the proposed 
biomarker. Clinical utility is tested in retrospective then prospective studies to show 
evidence that the effect of a therapeutic intervention on a clinical endpoint (e.g. 
mortality) can reliably be predicted by QCT. The final step in this process is qualification 
of the biomarker by regulatory bodies, such as the FDA, for use in therapeutic trials and 
routine clinical practice (17). To date, none of the available QCT methods have 
completed this process.  
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Current Imaging Analysis Methods for IPF Evaluation 
Imaging Protocols  
Standardized imaging acquisition is crucial for QCT (18). Volumetric acquisition with 
contiguous thin section reconstruction is important, with slice thickness usually around 1 
mm. Since the depth of inspiration can be a major source of variation, coaching the 
patient to comply with standardized breathing instructions is critical. Computed 
tomography (CT) radiation dose used for the acquisition is variable, but can be relatively 
low, and further reduced by dose modulation. For image reconstruction, a relatively 
“soft” kernel is used to avoid excessive noise; sharper acquisitions can also be 
acceptable if a denoising or kernel normalization technique is used (19). Iterative 
reconstruction techniques are not recommended until the effects of this reconstruction 
on textural analysis can be clearly understood. To ensure that QCT measurements are 
comparable, patients should be imaged using the same technique, ideally on the same 
CT scanner, at all timepoints. The utility of CT phantom acquisition (20) in clinical trials 
has not been established but may assist with machine calibration and correct 
implementation of an acquisition protocol before data collection begins.  
 
Visual Semi-Quantitative Scoring  
A CT pattern of usual interstitial pneumonia (UIP) is associated with higher mortality in 
fibrotic lung disease (21-23). Additionally, the extent of fibrosis on HRCT has been 
consistently linked to mortality in IPF in numerous studies (4, 24-27). Most outcome 
studies involving HRCT in IPF have focused on the ability of baseline HRCT patterns to 
predict outcome, but few have evaluated the ability of serial HRCT changes over a 
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specific follow-up period to predict outcome. Semi-quantitative HRCT evaluation is 
prone to inter- and intra-observer variability and may be too insensitive to capture 
clinically important short-term changes (28). 
Despite the large and consistent body of literature indicating a prognostic role for 
HRCT in IPF, HRCT-based biomarkers are neither routinely used in clinical practice nor 
incorporated as clinical endpoints in therapeutic trials for several reasons. First, visual 
assessment of HRCT patterns is subjective, with significant inter-observer variation, 
even among expert radiologists. For example, honeycombing has consistently 
demonstrated prognostic significance in many studies over the past 15 years (29-33) 
yet the inter-observer agreement for the presence of this pattern is moderate at best (4, 
31, 34). Second, it is not yet clear how HRCT pattern and extent can help inform 
management decisions in an individual patient. Unlike in oncology, where an image-
based disease stage maps directly to a management strategy, CT-based staging is not 
yet routinely used in IPF, although attempts have been made to do so (35-37). 
 
Computer-based Quantitative Scoring Systems 
Although computer assisted diagnosis (CAD) algorithms for classifying HRCT patterns 
have existed for decades (38), recent advances in computer processing power have 
enabled a groundswell of renewed interest in computer-assisted HRCT image analysis. 
In recent years, some of these tools have been used to analyze CT imaging data in 
clinical trials both retrospectively and prospectively. Below is a summary of some of the 
available computer-based methods for quantifying disease on HRCT that have been 
used to evaluate clinical trial populations in IPF (Table 1). There is currently no 
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consensus regarding the optimal method for QCT analysis and this review should not 
be interpreted as a comparison of their strengths and limitations. 
 
Histogram Kurtosis/Density Measures 
The Hounsfield unit (HU) scale is a measurement of relative densities (attenuation) 
determined by CT. In the lung parenchyma, CT attenuation measured in HU, is 
determined by the relative amounts of air, soft tissue, and blood in each volume element 
(voxel). The CT histogram provides a distribution of HU for an individual CT image or for 
the entire lung, permitting calculation of mean lung attenuation, variance, skewness, 
entropy, and kurtosis. Kurtosis describes the sharpness of the histogram peak and is 
inversely proportional to the thickness of the two tails of the histogram. Since lung 
fibrosis or inflammation causes an increase in the amount of soft tissue in the lung, it 
will increase mean lung attenuation, and thereby decrease the sharpness of the 
histogram peak (kurtosis) and the degree of leftward skewness of the curve (Figure 1). 
Mean lung attenuation, skewness, and kurtosis can therefore be used as measures of 
the extent of lung fibrosis. Generally, a large value of kurtosis indicates mild fibrosis 
whereas low kurtosis (i.e. close to 0 or negative) indicates moderate to severe fibrosis 
(39). Kurtosis and skewness of a histogram are known to be correlated with changes in 
FVC and overall survival in patients with IPF (15, 40). 
 
Adaptive Multiple Features Method (AMFM) 
The Adaptive Multiple Feature Method (AMFM) is a computer-based texture analysis 
tool that quantifies lung parenchymal patterns on CT. During development, the AMFM 
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tool was trained on various parenchymal patterns using 31x31 pixel regions of interest 
(image patches) extracted from CT images (41-43). Ground truth labeling of image 
patches was provided by the consensus vote of a group of experienced observers (43). 
During training, the AMFM narrows the texture in a training set image patch to a small 
number of optimal features for classification which are then applied to a test set via a 
Bayesian classifier. The kappa statistic of agreement between the regions, for which 
most observers agreed on the pattern type, versus the AMFM tool was 0.62 (43). This 
technique has been extended to 3-dimensional texture analysis (44, 45) and used to 
explore the association between the AMFM regional characterization of the lung and 
outcomes in IPF patients (46) (Figure 2). Among patients with IPF enrolled in clinical 
therapeutic trials, both visual and AMFM measurement of baseline extent of mixed 
ground glass and reticular (GGR) densities predicted subsequent disease progression 
(defined as composite death, hospitalization, or >10% FVC decline), independent of 
baseline age, gender, and FVC. Additionally, post-baseline change in GGR correlated 
with post-baseline change in FVC. The authors concluded that the AMFM provides an 
automated method of supporting existing prognostic markers and can enrich a study 
population with subjects at greatest risk of disease progression. A challenge, to date, 
with the application of the AMFM is the alteration of texture by scanning protocols. 
Legacy data used in the testing of the AMFM to date has required the use of a mixture 
of scan protocols and poor control of lung volume. More recent multi-center studies 
have established cross manufacturer protocols that serve to more closely align image 
characteristics (47).  
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CALIPER 
The automated lung parenchymal characterization by CALIPER (Computer-Aided Lung 
Informatics for Pathology Evaluation and Rating) uses a computer-vision based 
technique that includes volumetric local histogram and morphologic analysis to provide 
quantitative assessment of pulmonary parenchymal disease on HRCT data. This 
process automatically labels each pixel of a volumetric HRCT as belonging to one of 7 
specific parenchymal features: normal, ground glass opacity, reticular density, 
honeycombing and mild, moderate or severe low attenuation areas. The CALIPER 
classifier of lung parenchyma was developed from training sets of pathologically proven 
ILD and control subjects’ HRCT data obtained for the Lung Tissue Research 
Consortium (LTRC) (48) (Figure 3). Although technical features of acquisition and 
reconstruction are important to reproducibility of quantitative measures, the CALIPER 
measures have been shown to be reproducible and robust across a wide variety of 
acquisition and reconstruction techniques, including low (about 1-2mSv) and ultra-low 
(0.1 to 0.3mSv) dose CT techniques with both filtered-back-projection and iterative 
reconstruction techniques (49). 
 The CALIPER tool has been used retrospectively on thousands of datasets from 
multiple institutions and for prospective analysis of approximately 3000 HRCT scans 
acquired for the LTRC. It has been successfully used to predict survival and future 
physiologic change (such as FVC decline) in a variety of fibrotic lung diseases such as 
IPF, fibrotic non-specific interstitial pneumonia (NSIP), hypersensitivity pneumonitis 
(HP), unclassifiable ILD, and mixed processes such as combined pulmonary fibrosis 
and emphysema (50-55). Furthermore, a CALIPER-derived HRCT measure of 
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“pulmonary vascular-related structures” (PVRS) provides highly discriminative 
prognostic information in IPF, connective tissue disease related ILD, HP and 
unclassifiable ILD. Using additional automated clustering, the CALIPER characterization 
has been used to phenotype disease and automatically stratify subjects into sub-groups 
with prognostic value in 1322 LTRC scans (56, 57). CALIPER has also been utilized 
prospectively in a double-blind, placebo-controlled, phase 2 clinical trial of a novel anti-
fibrotic drug for IPF, using spirometrically-controlled HRCT at baseline and 28 weeks. 
The mean change in lung volumes and percent interstitial lung abnormalities (sum of 
ground glass, reticular densities and honeycombing) was evaluated as a secondary 
endpoint (58).  
 
Quantitative Lung Fibrosis (QLF) 
QLF is part of a panel of measures including quantitative honeycomb (QHC), ground 
glass (QGG) and composite interstitial lung disease (QILD) scores (59). In the discovery 
phase, the denoised texture features and support vector machine (SVM) demonstrated 
robustness in quantitative features across different scanner models and in classifying 
normal patterns (60). In validation, a five-step process was automated: (1) denoise; (2) 
voxel sampling; (3) calculate texture features; (4) run SVM classifier; and (5) output 
scores as ratios (percentage) or volumes (milliliters). Analytic validation has been 
reported: QLF demonstrated a good performance with visual scoring area under the 
curve (AUC) of 0.96 for detection and quantitation of diffuse lung disease, a short-term 
repeatability coefficient (RC) of 0.4% for whole lung and 2% for the most severe lobe 
within a subject (39, 60, 61). The QLF classifier has utilized robustness-driven feature 
Page 12 of 41 AJRCCM Articles in Press. Published on 09-July-2018 as 10.1164/rccm.201803-0444PP 
 Copyright © 2018 by the American Thoracic Society 
13 
 
selection to improve robustness against slice thickness, reconstruction kernel, and tube 
current without sacrificing performance. Cut points based on the repeatability measures 
have been frozen and QLF and QILD extent at baseline are prognostic of survival and 
FVC impairment (Figure 4). As surrogate outcomes, QLF and QILD scores have been 
clinically utilized in 2,059 HRCT scans from 1,136 subjects in 7 IPF clinical trials 
showing both treatment efficacy and correlation with FVC change.  
 
Data-driven Textural Analysis (DTA) 
DTA is based on unsupervised feature learning and is implemented as a simple 
convolutional neural network (CNN). The convolutional weights are pre-computed in an 
initial clustering process on a large collection of unlabeled images (62). The network is 
trained as a binary classifier using radiologist-labeled regions of interest (ROIs) 
demonstrating normal parenchyma and UIP patterns. DTA fibrosis score is calculated 
as the number of ROIs classified as fibrotic divided by the total number of ROIs 
sampled from a lung segmentation volume (Figure 5).  
Analytic validation in 280 subjects enrolled in IPF Network trials showed that 
extent of fibrosis measured by DTA correlates with physiologic impairment at baseline 
(FVC percentage predicted ρ=-0.60, p<0.001; diffusing capacity for carbon monoxide 
(DLCO) percentage predicted ρ=-0.68, p<0.001). Responsiveness was tested in a 
subset of 72 subjects with 15-month follow-up HRCT. Change in DTA score was 
correlated with change in FVC percentage predicted (ρ=-0.41, p<0.001) and DLCO 
percentage predicted (ρ=-0.40, p<0.001). Receiver Operating Characteristic (ROC) 
analysis indicated that an increase in DTA score of 5.5% at follow-up identified subjects 
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who experienced a 5% absolute decline in FVC percentage predicted (63). In a 
separate retrospective cohort study of 501 IPF subjects enrolled in an interventional 
clinical trial, increase in baseline DTA score was associated with increased risk of 
disease progression and all-cause hospitalization (unpublished data).  
 
Functional Respiratory Imaging (FRI) 
FRI is a combination of low-dose HRCT scans taken at inspiration and expiration, and 
computer-based flow simulations. The data acquisition procedure includes respiratory 
gating using a handheld spirometer to ensure correct and repeatable lung volumes (64).  
FRI enables regional quantification of lung structure and function and is validated in 
obstructive lung diseases through comparisons with conventional lung function 
measures, isotope-based techniques, hyperpolarized helium, exercise tolerance and 
patient reported outcomes (65-67). Test/retest data and repeated baseline scans show 
very low variability (1-3%) for airway volumes, blood vessel volumes and airway 
resistances (68, 69). This low variability is due to the rigorously controlled and 
respiratory-gated way HRCT scans are obtained, in combination with a standardized 3D 
reconstruction of the anatomical structures. FRI enables regional quantification of lung 
structure and function using standardized 3D reconstruction of the anatomical structures 
(65) (Figure 6). By focusing on the anatomy (e.g. airway and blood volumes) rather than 
individual voxels, the variability induced by noise or reconstruction algorithms 
associated with low dose HRCT scans can be reduced.  
Recent studies in IPF showed that disease progression, as determined by FVC 
decline, is associated with a reduction in CT measured lung volumes (R2=0.80, 
Page 14 of 41 AJRCCM Articles in Press. Published on 09-July-2018 as 10.1164/rccm.201803-0444PP 
 Copyright © 2018 by the American Thoracic Society 
15 
 
p<0.001) and an increase in relative airway volumes (R2=0.29, p<0.001). Changes in 
FVC are correlated with changes in lung volumes (R2 = 0.18, p < 0.001) and changes in 
relative airway caliber (R2=0.15, p<0.001) (70). Lobe and airway volumes can already 
be significantly affected by IPF while conventional measures such as FVC remain within 
the normal (healthy) range (71). IPF disease progression manifests itself 
heterogeneously in terms of FRI parameters, with the lower lobes consistently more 
affected than the upper lobes. In a recent small drug trial (NCT02738801) using a novel 
autotaxin inhibitor, FVC showed a positive but non-significant signal of 95 ml between a 
treatment and placebo arm after 12 weeks of treatment. FRI parameters confirmed the 
treatment signal with statistical significance (unpublished data). While FRI is a 
promising technique, additional studies need to be done to further utilize FRI as a 
standard drug development tool and to determine minimal clinically important difference 
(MCID). 
 
Advantages of QCT 
Visual CT features (72), derived from two-dimensional interspaced HRCT imaging in the 
1980s (73-76), were primarily designed to provide qualitative information that aided 
diagnosis. As the focus of CT analysis in ILD moves to prognostication on volumetric 
baseline and longitudinal CTs, the precision, sensitivity and absence of inter-observer 
variability associated with QCT have made it an increasingly attractive substitute for 
visual CT analysis. Quantifying subtle changes in CT features using computer analysis 
is likely to play an important role in the identification of treatment efficacy in an era of 
newly emerging drug therapies in fibrosing lung disease.  
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QCT-derived features have outperformed visual CT variables in predicting 
outcome across several fibrosing lung diseases with diverse radiographic patterns, 
demonstrating its utility is not limited to the usual interstitial pneumonia pattern (57, 77, 
78). Additionally, interrogation of three-dimensional datasets by advanced computer 
vision and deep learning algorithm techniques may also permit identification of novel 
biomarkers of disease and prognostic CT features. Rapid and reproducible QCT 
analysis will likely become increasingly important in following subjects with interstitial 
lung abnormalities identified incidentally on CT, or during lung cancer screening (79-81). 
 
Disadvantages of QCT 
QCT has several limitations. First, most published approaches involve segmentation 
and feature extraction based on lung density (measured in HU), which is heavily 
influenced by CT dose, slice thickness, and reconstruction kernel, including new 
iterative reconstructions (59). Second, patient-related factors such as inspiratory 
volume/effort can significantly impact QCT feature characterization. Thorough coaching 
of patients regarding inspiratory effort and timing, or spirometric control of studies would 
greatly facilitate reproducibility of results (82) but would significantly increase the 
complexity of performance in routine clinical practice. Establishing limits of variation, 
and possibly adjustment for lung volume, may help to resolve this limitation (83). Third, 
the availability of a non-contrast, volumetric thin high-resolution CT dataset with a CT 
kernel that does not alter local HU accuracy is essential to accurate feature extraction. 
This may limit the utility of QCT in retrospective CT datasets, as clinical scans 
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commonly are reconstructed with parameters that utilize edge-enhancing algorithms to 
increase the visual conspicuity of some pulmonary features.  
Clinical Application of an Image-based Biomarker 
The immediate applicability of QCT relates to its potential role in clinical trials. Its use 
may be considered in the following clinical settings: to stratify patients by disease 
severity, with theoretical advantages over pulmonary function tests (avoiding the 
confounding effect of the normal range) and visual HRCT scoring (avoiding inter-
observer variation), and as a longitudinal predictor of early mortality. Validation would 
require that serial QCT predict mortality more accurately than serial FVC. 
 
Summary 
There is an urgent need to develop sensitive, reproducible and objective biomarkers in 
IPF that can be used to monitor disease progression and therapeutic response. QCT 
provides an objective measure of disease extent and an opportunity to detect subtle 
disease progression. Therefore, understandably, QCT has been the focus of intensive 
biomarker research over the past decade. However, despite a growing body of literature 
demonstrating the potential of QCT, several questions remain unanswered. First, it is 
unclear if QCT can predict response to therapy using baseline data in an individual 
patient with IPF (i.e. QCT is un-proved as a predictive factor). Second, QCT has not 
been shown to reliably identify treatment failure early in a trial of therapy. While serial 
QCT has been applied in clinical trials with interesting results, additional prospective 
biomarker studies will need to be performed to show that progression of fibrosis by QCT 
can be used as a surrogate outcome biomarker.  
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Table 1. 
 
QCT Method Key findings in IPF 
Histogram/Kurtosis  
analysis 
1. Kurtosis and skewness on histogram analysis are 
associated with the changes in physiology and overall 
survival in patients with IPF (15, 40). 
AMFM 
 
1. AMFM was shown to be superior to earlier quantitative CT-
based metrics including mean lung density and histogram-
based metrics in distinguishing between normal 
parenchyma and parenchyma from IPF or sarcoid patients 
(42).  
2. AMFM enhanced with 3D texture and a support vector 
machine classifier was shown to have a better than 90% 
sensitivity and specificity in classifying 5 simultaneous 
regional textures including emphysema, ground glass, and 
honeycombing (44, 45). 
3. AMFM measurement of baseline extent of mixed ground 
glass + reticular densities (GGR) predicts subsequent 
disease progression (death, hospitalization, or >10% FVC 
decline), and post-baseline GGR change correlates with 
post-baseline FVC change (46). 
 
CALIPER 
 
1. CALIPER ILD variables and vessel-related structures can 
predict lung function tests and improve on visual CT scores 
(51, 84). 
2. Vessel-related structure scores better predict mortality than 
baseline visual CT scores in IPF (77). 
3. Compared to IPF alone patients with combined fibrosis and 
emphysema do not have worsened outcomes (52) or 
increased likelihoods of pulmonary hypertension (85) 
beyond that explained by extents of ILD and emphysema. 
4. CALIPER ILD variables and vessel-related structures better 
predict lung function decline than longitudinal visual CT 
scores (55). 
5. Change in CALIPER features predict survival (86). 
6. Change in CALIPER features can help distinguish between 
IPF and NSIP in difficult to diagnose cases (87). 
7. Stability of CALIPER normal lung parenchymal volumes in a 
phase I therapeutic study (88). 
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QLF/QILD 
 
1. QLF/QILD measurements have been developed to 
overcome the variations due to CT technical parameters 
from the multi-center trials (59). 
2. QLF scores has been evaluated as the part of the analytic 
validation with visual scores (59). 
3. QLF scores have been clinically validated after locking the 
algorithm (60, 61).  
4. An automated QLF/QILD system has been implemented 
and validated to be ready for clinical trials, which is an 
important part prior to the clinical utilities (60). 
5. Changes in QLF and QILD scores were associated with the 
changes in FVC, FEV1, and DLCO (surrogate outcomes) 
(39, 89). 
6. Week 24 changes in QLF predict FVC changes in week 36 
and 48 (61). 
7. Used in 6 phase II trials as secondary or exploratory 
outcomes and 1 phase IIIb trial as a primary endpoint
 
(NCT01979952). 
DTA 
 
1. DTA fibrosis is associated with visual assessment and 
baseline lung function and change in DTA fibrosis extent on 
sequential scans is associated with change in function (90). 
2. Greater baseline DTA score is associated with increased 
risk of disease progression and all-cause hospitalization 
(63). 
3. Subjects with disease progression at visual assessment had 
greater DTA fibrosis extent and poorer lung function at 
baseline and had greater rates of change in these indexes 
over the follow-up period (90). 
4. In two IPF clinical trial populations with sequential scans, an 
increase of 5.5% in DTA fibrosis extent was associated with 
progression determined as 5% decline in FVC (unpublished 
data). 
 
FRI 
 
1. Lobe volumes decrease with progressing disease with lower 
lobes more affected than upper lobes for all FVC values 
(71). 
2. Airway volumes, corrected for lung volumes, increase with 
progressing disease with the increase driven by pressure 
redistribution and traction bronchiectasis (71). 
3. Lobe volumes and airway volumes could already be 
severely affected by IPF even when FVC is normal (71). 
4. Baseline FRI parameters have the potential to predict 
treatment success (70). 
5. Endpoints describing changes in regional anatomical 
structure and function have the potential to be more 
sensitive than FVC resulting in smaller and shorter clinical 
trials (71). 
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Figure Legend 
Figure 1. Two patients with mild and severe IPF (FVC 65%, and 47%, respectively): 
kurtosis measures are 5.00, and 0.41 in subjects with mild and severe IPF, respectively. 
Corresponding skewness measures are 1.48, and 0.80.  [Reprinted with permission 
from Kim et al Acad Radiol. 2015] 
 
Figure 2. Four-panel sets serving as examples of regional AMFM-derived results for 
two patients with IPF. Unlabeled dorsal (top) and mid (bottom) level coronal sections 
are shown in the left panels obtained from a subject with lower (top set) and a subject 
with higher (bottom set) proportion of lung voxels/regions characterized as representing 
a ground glass reticular (GGR) texture pattern. The right panels show regional 
transparent color overlays representing the parenchymal characteristic determined by 
the AMFM from the regional image texture. A higher proportion of lung characterized as 
GGR on a baseline HRCT was associated with increased risk of disease progression 
among IPF subjects enrolled in a clinical therapeutic trial. Colors represent: Ground 
Glass (Green), Normal (White), Ground Glass-Reticular (Blue), Bronchovascular 
(Brown), and Honeycomb (Yellow). 
 
Figure 3. Axial CT image of UIP with CALIPER characterization. Top: Reticulation, 
ground glass opacity and traction bronchiectasis are visible in both lower lobes and the 
anterior right middle lobe, with a honeycomb cyst visible in the left lower lobe. Middle: 
Color overlay image highlighting parenchymal features characterized by CALIPER: 
normal lung (light and dark green) surrounds areas of ground glass opacity (yellow), 
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reticulation (orange) and the left lower lobe honeycomb cyst (red). Bottom: Pulmonary 
vessel volume quantified by CALIPER is an analytic feature that includes pulmonary 
arteries, veins, and other small branching/linear structures in areas that contain more 
severe fibrosis.  
 
Figure 4. Coronal and sagittal CT images at baseline and 12 months with QLF 
characterization: Top: original images of coronal (left) and sagittal (right) images, 
Bottom: annotated coronal and sagittal HRCT images with the classification of 
quantitative lung fibrosis (QLF) (blue +red). Center: a paired set of 5D plots with 3 
dimensional locations, QLF scores, and temporal information at baseline and 12 
months, where the circle size indicates QLF score and an orange circle indicates the 
most severe lobe (left lower lobe). QLF increased from 12% to 17% in the left lower 
lobe. In whole lung, QLF increased from 9% to 14% over 12 months.  
 
Figure 5. Axial chest CT section of a subject with UIP (left). Classification results (right) 
show regions classified as normal (green), airway (blue), reticular abnormality (yellow) 
and honeycombing (red). DTA score is the percentage of lung volume occupied by 
reticular abnormality or honeycombing. 
 
Figure 6. Patient specific reconstruction of fibrosis (green), distal airways (blue), central 
airways (gray), emphysema (black) and blood vessels (red) using Functional 
Respiratory Imaging (FRI). 
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